慢性阻塞性肺疾病患者使用雾化长效β2受体激动剂的指导原则：专家小组共识
Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus.
作者信息
Wise Robert A, Acevedo Russell A, Anzueto Antonio R, Hanania Nicola A, Martinez Fernando J, Ohar Jill A, Tashkin Donald P
机构信息
Johns Hopkins University School of Medicine, Baltimore, Maryland.
Crouse Hospital, Syracuse, New York.
出版信息
Chronic Obstr Pulm Dis. 2016 Nov 15;4(1):7-20. doi: 10.15326/jcopdf.4.1.2016.0141.
Abstract
Determining which patients with COPD may benefit from a nebulized long-acting beta2-agonist (LABA) is a challenge in current practice. In the absence of strong clinical guidelines addressing this issue, an expert panel convened to develop guiding principles for the use of nebulized LABA therapy in patients with COPD. This article summarizes these guiding principles and other practical issues discussed during a roundtable meeting.
摘要
确定哪些慢性阻塞性肺疾病（COPD）患者可能从雾化吸入长效β2受体激动剂（LABA）中获益是当前临床实践中的一项挑战。由于缺乏针对这一问题的强有力临床指南，一个专家小组召开会议，制定COPD患者雾化吸入LABA治疗的指导原则。本文总结了这些指导原则以及在一次圆桌会议上讨论的其他实际问题。
相似文献
1
Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus.慢性阻塞性肺疾病患者使用雾化长效β2受体激动剂的指导原则：专家小组共识
Chronic Obstr Pulm Dis. 2016 Nov 15;4(1):7-20. doi: 10.15326/jcopdf.4.1.2016.0141.
2
Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β2-agonists.接受雾化长效β2受体激动剂治疗的商业保险慢性阻塞性肺疾病患者的病情加重、医疗服务利用及费用情况
J Med Econ. 2016;19(1):11-20. doi: 10.3111/13696998.2015.1079530. Epub 2015 Sep 11.
3
Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β-agonist bronchodilators.目前有证据表明，使用长效抗胆碱能药物/长效β受体激动剂双支气管扩张剂治疗 COPD 有效。
Postgrad Med. 2020 Mar;132(2):198-205. doi: 10.1080/00325481.2019.1702834. Epub 2020 Jan 3.
4
Role of Long-Acting Muscarinic Antagonist/Long-Acting β-Agonist Therapy in Chronic Obstructive Pulmonary Disease.长效毒蕈碱拮抗剂/长效β受体激动剂疗法在慢性阻塞性肺疾病中的作用
Ann Pharmacother. 2017 Aug;51(8):696-705. doi: 10.1177/1060028017705149. Epub 2017 Apr 14.
5
Twenty-five statements on early initiation of fixed combination ICS/LABA treatment for asthma and COPD in primary and secondary care: consensus research by a modified Delphi process.关于在初级和二级医疗保健中对哮喘和慢性阻塞性肺疾病（COPD）早期启动吸入性糖皮质激素/长效β2受体激动剂（ICS/LABA）联合治疗的25条声明：通过改良德尔菲法进行的共识研究
Pneumologie. 2012 Sep;66(9):549-57. doi: 10.1055/s-0032-1310076. Epub 2012 Aug 16.
6
Comparative Effectiveness of Long-Acting Beta -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease.长效β受体激动剂联合长效毒蕈碱拮抗剂或吸入性糖皮质激素治疗慢性阻塞性肺疾病的比较疗效
Pharmacotherapy. 2017 Apr;37(4):447-455. doi: 10.1002/phar.1913.
7
Reduction in Hospital Readmission Rates Among Medicare Beneficiaries With Chronic Obstructive Pulmonary Disease: A Real-world Outcomes Study of Nebulized Bronchodilators.慢性阻塞性肺疾病 Medicare 受益人群的住院再入院率降低：雾化支气管扩张剂的真实世界结局研究。
Clin Ther. 2019 Nov;41(11):2283-2296. doi: 10.1016/j.clinthera.2019.09.001. Epub 2019 Oct 17.
8
Inhaled treatment of COPD: a Delphi consensus statement.慢性阻塞性肺疾病的吸入治疗：一份德尔菲共识声明。
Int J Chron Obstruct Pulmon Dis. 2017 Mar 6;12:793-801. doi: 10.2147/COPD.S125564. eCollection 2017.
9
Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.长效β2受体激动剂联合噻托溴铵与单独使用噻托溴铵或长效β2受体激动剂治疗慢性阻塞性肺疾病的比较
Cochrane Database Syst Rev. 2015 Oct 22;2015(10):CD008989. doi: 10.1002/14651858.CD008989.pub3.
10
A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD.当前和正在开发的固定剂量 LABA/LAMA 联合治疗 COPD 的综述。
Expert Opin Pharmacother. 2017 Dec;18(17):1833-1843. doi: 10.1080/14656566.2017.1403583. Epub 2017 Nov 15.
引用本文的文献
1
Advances in Therapeutics for Chronic Lung Diseases: From Standard Therapies to Emerging Breakthroughs.慢性肺病治疗进展：从标准疗法到新兴突破
J Clin Med. 2025 Apr 30;14(9):3118. doi: 10.3390/jcm14093118.
2
Recalibrating Perceptions and Attitudes Toward Nebulizers versus Inhalers for Maintenance Therapy in COPD: Past as Prologue.重新校准慢性阻塞性肺疾病维持治疗中雾化器与吸入器的认知和态度：以史为鉴。
Int J Chron Obstruct Pulmon Dis. 2024 Nov 28;19:2571-2586. doi: 10.2147/COPD.S491275. eCollection 2024.
3
Inhaler device feature preferences among patients with obstructive lung diseases: A systematic review and meta-analysis.阻塞性肺疾病患者对吸入装置特性的偏好：一项系统评价和荟萃分析。
Medicine (Baltimore). 2020 Jun 19;99(25):e20718. doi: 10.1097/MD.0000000000020718.
4
Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis.软雾吸入器的设备使用错误：一项全球系统性文献综述与荟萃分析。
Chron Respir Dis. 2020 Jan-Dec;17:1479973119901234. doi: 10.1177/1479973119901234.
5
Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment.医疗保险受益人群中慢性阻塞性肺疾病患者使用雾化阿福特罗治疗的药物管理模式。
Int J Chron Obstruct Pulmon Dis. 2019 May 15;14:1019-1031. doi: 10.2147/COPD.S199251. eCollection 2019.
6
Nebulized Long-Acting Beta2-Agonists: More Than Just Bridging Gaps in the Management of Symptomatic COPD.雾化长效β2受体激动剂：不仅仅是填补症状性慢性阻塞性肺疾病管理中的空白。
Chronic Obstr Pulm Dis. 2017 Jan 5;4(1):1-3. doi: 10.15326/jcopdf.4.1.2016.0175.
本文引用的文献
1
Effectiveness of Interventions to Teach Metered-Dose and Diskus Inhaler Techniques. A Randomized Trial.定量气雾剂和都保吸入器技术教学干预措施的有效性：一项随机试验
Ann Am Thorac Soc. 2016 Jun;13(6):816-24. doi: 10.1513/AnnalsATS.201509-603OC.
2
Reducing excess readmissions: promising effect of hospital readmissions reduction program in US hospitals.减少不必要的再入院：美国医院再入院减少计划的显著效果
Int J Qual Health Care. 2016 Feb;28(1):53-8. doi: 10.1093/intqhc/mzv090. Epub 2015 Nov 15.
3
Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β2-agonists.接受雾化长效β2受体激动剂治疗的商业保险慢性阻塞性肺疾病患者的病情加重、医疗服务利用及费用情况
J Med Econ. 2016;19(1):11-20. doi: 10.3111/13696998.2015.1079530. Epub 2015 Sep 11.
4
Smoking duration, respiratory symptoms, and COPD in adults aged ≥45 years with a smoking history.有吸烟史的45岁及以上成年人的吸烟时长、呼吸道症状与慢性阻塞性肺疾病
Int J Chron Obstruct Pulmon Dis. 2015 Jul 21;10:1409-16. doi: 10.2147/COPD.S82259. eCollection 2015.
5
Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病中延长的急性加重期恢复的影响
Am J Respir Crit Care Med. 2015 Oct 15;192(8):943-50. doi: 10.1164/rccm.201412-2269OC.
6
Identifying cases of undiagnosed, clinically significant COPD in primary care: qualitative insight from patients in the target population.在基层医疗中识别未确诊的、具有临床意义的 COPD 病例：目标人群中患者的定性见解。
NPJ Prim Care Respir Med. 2015 Apr 16;25:15024. doi: 10.1038/npjpcrm.2015.24.
7
Integrating COPD into Patient-Centered Hospital Readmissions Reduction Programs.将慢性阻塞性肺疾病纳入以患者为中心的减少医院再入院计划。
Chronic Obstr Pulm Dis. 2015;2(1):70-80. doi: 10.15326/jcopdf.2.1.2014.0148.
8
A new algorithm for the management of COPD.一种用于慢性阻塞性肺疾病管理的新算法。
Lancet Respir Med. 2015 Apr;3(4):266-8. doi: 10.1016/S2213-2600(15)00091-0.
9
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease.美国胸科学会/欧洲呼吸学会官方声明：慢性阻塞性肺疾病研究问题。
Am J Respir Crit Care Med. 2015 Apr 1;191(7):e4-e27. doi: 10.1164/rccm.201501-0044ST.
10
Patients' practices and experiences of using nebuliser therapy in the management of COPD at home.患者在家中使用雾化器治疗 COPD 的实践和经验。
BMJ Open Respir Res. 2015 Feb 24;2(1):e000076. doi: 10.1136/bmjresp-2014-000076. eCollection 2015.
Zotero 插件